These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

105 related items for PubMed ID: 2117787

  • 1. Praziquantel in the treatment of hepatosplenic schistosomiasis: biochemical disease markers indicate deceleration of fibrogenesis and diminution of portal flow obstruction.
    Zwingenberger K, Richter J, Vergetti JG, Feldmeier H.
    Trans R Soc Trop Med Hyg; 1990; 84(2):252-6. PubMed ID: 2117787
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Liver involvement in human schistosomiasis mansoni. Assessment by immunological and biochemical markers.
    Zwingenberger K, Feldmeier H, Queiroz JA, Siqueira JG, Auto HF, Alencar JE, Bienzle U.
    Parasitol Res; 1988; 74(5):448-55. PubMed ID: 3137558
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Hepatosplenic schistosomiasis: case report and clinical review].
    Wirth HP, Casanova C, Meyenberger C, Hammer B, Ammann R, Blum HE.
    Schweiz Med Wochenschr; 1993 Oct 23; 123(42):1991-5. PubMed ID: 8259482
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Praziquantel in the treatment of the hepatosplenic form of Schistosomiasis mansoni.
    da Silva LC, Sette H, Christo CH, Sáez-Alquezar A, Carneiro CR, Lacet CM, Ohtsuki N, Raia S.
    Arzneimittelforschung; 1981 Oct 23; 31(3a):601-3. PubMed ID: 7195256
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of hepatosplenic Schistosomiasis mansoni with praziquantel. Preliminary report on tolerance and efficacy.
    Coutinho A, Domingues AL, Neves J, Almeida ST.
    Arzneimittelforschung; 1983 Oct 23; 33(5):787-91. PubMed ID: 6683560
    [No Abstract] [Full Text] [Related]

  • 14. Enzyme activities and protein concentrations in serum of patients with hepatosplenic schistosomiasis.
    Abdel-Rahim IM, Kaiser C, Homeida M, Elsheikh M, Schmidt E, Ehrich JH, Doehring-Schwerdfeger E.
    Trop Med Parasitol; 1990 Sep 23; 41(3):262-4. PubMed ID: 1701559
    [Abstract] [Full Text] [Related]

  • 15. Assessment of portal hemodynamics by Doppler ultrasound and of liver morphology in the hepatosplenic and hepatointestinal forms of schistosomiasis mansoni.
    Vezozzo DC, Farias AQ, Cerri GG, Da Silva LC, Carrilho FJ.
    Dig Dis Sci; 2006 Aug 23; 51(8):1413-9. PubMed ID: 16868833
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of the cytokines IL-10 and IL-13 as mediators in the progression of Symmers fibrosis in patients with hepatosplenic schistosomiasis mansoni.
    Brandt CT, Rino M, Pitta MG, Muniz JS, Silveira Dde O, Castro CM.
    Rev Col Bras Cir; 2010 Oct 23; 37(5):333-7. PubMed ID: 21180998
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hypoprothrombinemia in the compensated form of hepatosplenic schistosomiasis: further studies.
    Manoukian N, Borges DR.
    Rev Inst Med Trop Sao Paulo; 1988 Oct 23; 30(4):274-80. PubMed ID: 3149416
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.